Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Biosecurity

    Why is the Defense Department Withholding Funding for USAMRIID and CCDC Chemical Biological Center?

    By Global Biodefense StaffFebruary 5, 2020
    Share
    Facebook LinkedIn Reddit Email

    Today, U.S. Senators Chris Van Hollen and Ben Cardin as well as Congressmen David Trone, Dutch Ruppersberger, Jamie Raskin, and Anthony Brown (all D-Md.) raised concerns in a letter to U.S. Secretary of Defense Mark Esper regarding funding for the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) and the U.S. Army Combat Capabilities Command (CCDC) Chemical Biological Center at Aberdeen Proving Ground.

    On Thursday of last week, the members were informed that the two programs are facing a withholding of more than $100 million in funds by the Office of the Under Secretary of Defense for Acquisition and Sustainment.

    Senators Van Hollen and Cardin immediately arranged a meeting on Friday with General John Murray, Commanding General, Army Futures Command, and Brigadier General Michael Talley, Commanding General, USAMRIID and Fort Detrick, to discuss the issue. At that meeting, both General Murray and General Talley shared their commitment to assuring adequate resources to preserve USAMRIID’s important mission. Other members of the Maryland delegation met or spoke with Army leadership separately. The members are working to ensure that the labs are properly funded and staffed, and in doing so, sent a letter to Secretary Esper.

    The members write, “As our nation prepares to confront the coronavirus global health emergency, we write to express our concern regarding the Office of the Under Secretary of Defense for Acquisition and Sustainment (OUSD(A&S)) withholding $104 million in payments to the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) at Fort Detrick and the U.S. Army Combat Capabilities Command (CCDC) Chemical Biological Center at Aberdeen Proving Ground.”

    They continue, “Given the critical contributions of USAMRIID and the CCDC Chemical Biological Center to our national security, including their role in responding to the coronavirus outbreak, we were alarmed to learn that the OUSD(A&S) has withheld payment for laboratory research since September 2019.”

    They close the letter, stating, “We urge you to work with the Office of the Under Secretary of Defense for Acquisition and Sustainment to promptly release the funds necessary for the continued operation of USAMRIID and the CCDC Chemical Biological Center and ensure that the Department is more transparent with its budgeting decisions in the future. Additionally, we ask that the Army and the OSD provide our offices with an update no later than February 28, 2020 on the progress made toward resolving any outstanding issues and releasing any remaining withheld funds.”

    The text of the letter is available here and below:


    Dear Secretary Esper:

    As our nation prepares to confront the coronavirus global health emergency, we write to express our concern regarding the Office of the Under Secretary of Defense for Acquisition and Sustainment (OUSD(A&S)) withholding $104 million in payments to the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) at Fort Detrick and the United States Army Medical Research Institute of Chemical Defense (USAMRICD) at Aberdeen Proving Ground.

    As you know, USAMRIID is the Department’s lead laboratory for medical biological defense research. Their research helps to protect the American warfighter from biological threats and investigate disease outbreaks and threats to public health. Research conducted at USAMRIID leads to therapeutics, vaccines, diagnostics, and information that benefit military personnel and civilians. USAMRICD is the nation’s leading science and technology laboratory in the area of medical chemical countermeasures research and development.

    Given the critical contributions of USAMRIID and USAMRICD to our national security, including their role in responding to the coronavirus outbreak, we were alarmed to learn that the OUSD(A&S) has withheld payment for laboratory research since September 2019.

    Furthermore, we express concern that OUSD(A&S) is considering reducing the operational capacity at USAMRIID and USAMRICD. As you know, missions that require both a highly-skilled workforce and the ability to surge in times of crisis, like chemical and biological research, cannot simply be slashed when no emergency is present. The men and women who are the heart of these laboratories have numerous opportunities available to them. This capacity, once reduced, cannot be rebuilt overnight.

    Lastly, in a November 2019 letter, Members of Congress expressed their concern to you regarding the Defense Department’s continuing efforts to make drastic programmatic changes without consulting Congress. As we have previously made clear, senior level budget reviews from the Office of the Secretary of Defense must be coordinated with Congress to ensure we are adhering to our Constitutional obligations.

    We urge you to work with the Office of the Under Secretary of Defense for Acquisition and Sustainment to promptly release the funds necessary for the continued operation of USAMRIID and USAMRICD and ensure that the Department is more transparent with its budgeting decisions in the future. Additionally, we ask that the Army and the OSD provide our offices with an update no later than February 28, 2020 on the progress made toward resolving any outstanding issues and releasing any remaining withheld funds.


    READ ALSO:

    Van Hollen, Cardin Tour Fort Detrick’s USAMRIID After Funding Withheld Frederick News Post

    Maryland’s Democratic lawmakers push back on Department of Defense withholding funding from APG, Fort Detrick Baltimore Sun

    Pentagon Withholding Funds from Army’s Top Medical Bio and Chem Labs Military Times

    Editor Pick Magazine Edition 6 Feb 2020 USAMRIID
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleHHS, Regeneron Collaborate to Develop COVID-19 Treatment Using VelociSuite Technology
    Next Article CDC Novel Coronavirus Diagnostic Ships Out to Public Health Labs

    Related Stories

    EPA Developing AMR Risk Framework for Antibacterial and Antifungal Pesticides

    September 29, 2023

    Provide Feedback on Federal DURC Biosafety Oversight of Potential Pandemic Pathogens

    September 24, 2023

    Committee to Examine Transmission and Geographic Spread of Chronic Wasting Disease

    September 24, 2023

    Jurata Thin Film and CastleVax Awarded Grant to Advance Thermostabilized COVID-19 Booster

    September 20, 2023
    News Scan

    Biodefense Headlines – 19 September 2023

    News Scan September 19, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include a global survey of gain-of-function research; funding of an mRNA mpox vaccine; Nipah virus outbreak in India; field detection of threat agents with acoustic…

    Upcoming Events

    Oct 3
    Virtual Event Virtual Event
    October 3 - October 5

    OneLab Summit 2023

    Oct 3
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships to Distribute, Dispense, and Administer Medical Countermeasures

    Oct 4
    Virtual Event Virtual Event
    10:00 am - 2:00 pm EDT

    Tunneling Nanotubes and Intracellular Protrusions Workshop

    Oct 12
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships for Acceptance and Uptake of Medical Countermeasures

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.

    We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are okay with it.OkPrivacy policy